NCT03170336 (ANTI-UPRO) is a Phase 4 clinical trial of Amiloride in Chronic Kidney Diseases, sponsored by Guangdong Provincial People's Hospital.

Who is sponsoring NCT03170336?

NCT03170336 is sponsored by Guangdong Provincial People's Hospital.

What drugs are being tested in NCT03170336?

Interventions in NCT03170336: Amiloride, Hydrochlorothiazide.

What condition does NCT03170336 study?

NCT03170336 studies Chronic Kidney Diseases.

Is NCT03170336 still recruiting?

NCT03170336 is currently completed. Last updated 18 September 2020.

Last reviewed 2020-09-18 · How we verify

NCT03170336: ANTI-UPRO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A New Application of Amiloride in the Treatment of Patient With Chronic Kidney Disease In Reducing Urinary PROtein

Completed Phase 4 Last updated 18 September 2020

What this trial tests

Phase 4 trial testing Amiloride in Chronic Kidney Diseases in 40 participants. Completed in 1 August 2020.

Timeline

1 March 2018

Primary endpoint
1 August 2020

1 August 2020

Quick facts

Lead sponsor	Guangdong Provincial People's Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	40
Start date	1 March 2018
Primary completion	1 August 2020
Estimated completion	1 August 2020
Sites	1 location across China

Drugs / interventions tested

Amiloride (AMILORIDE) — full drug profile →
Hydrochlorothiazide (hydrochlorothiazide) — full drug profile →

Conditions studied

Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →

Sponsor

Guangdong Provincial People's Hospital

Who can join

14 and older, any sex, with Chronic Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nowadays, the prevalence of chronic kidney disease (CKD) in China is about 10.8%,and nearly 120 million people suffer from CKD, which has become a serious public health problem in China. Study confirmed that proteinuria is an independent risk factor for the continuous deterioration of glomerular filtration rate (GFR) in patients with CKD. So it is of great significance to explore the strategy of reducing proteinuria. According to our previous study, Amiloride can inhibit the expression of uPAR in podocytes and reduce proteinuria, This clinical trial aims to evaluate the effect and safety of Amiloride in decreasing proteinuria for patients with Chronic Kidney Disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The effect of amiloride in decreasing albuminuria in patients with diabetic kidney diseases: a prospective, crossover, open-label study.
Li R, Xie Z, Zhang L, Huang Y, et al · · 2021 · cited 5× · PMID 33657976 · DOI 10.1080/0886022x.2021.1892759

Verify or expand the search:

Other trials of Amiloride

Trials testing the same drug.

NCT06224673 — ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer · Phase 2 · not yet recruiting
NCT05125237 — Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene · completed
NCT04331691 — Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension · Phase 4 · completed
NCT04181008 — Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers · EARLY_PHASE1 · completed
NCT05079789 — Amiloride in Nephrotic Syndrome · Phase 3 · terminated

Other recruiting trials for Chronic Kidney Diseases

Currently open trials in the same condition.

NCT06593392 — Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus · Phase 2 · recruiting
NCT07358572 — Eye-Brain-Kidney in CKD · recruiting
NCT06463483 — Automated Insulin Delivery in Adults With Advanced Kidney Disease · NA · recruiting
NCT06927024 — Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD) · NA · recruiting
NCT07115953 — Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension · NA · recruiting

Other Guangdong Provincial People's Hospital trials

Trials by the same sponsor.

NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT07514611 — Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial · NA · recruiting
NCT07352930 — A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Can · NA · not yet recruiting
NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
NCT07483398 — RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson's Disease · Phase 4 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03170336 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangdong Provincial People's Hospital
Last refreshed: 18 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03170336.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing